ashibio

āshibio is a private, pre-revenue biotech founded in 2018 and headquartered in Burlingame, California, USA, developing targeted antibody therapies for severe rare bone diseases. The company has two clinical-stage assets: andecaliximab (anti-MMP9) for heterotopic ossification disorders including FOP and non-hereditary HO, and vantictumab (anti-FZD) for autosomal dominant osteopetrosis type 2 (ADO2). With promising preclinical data presented and clinical trials underway or planned, āshibio is positioned in a niche, high-need therapeutic area with limited competition but faces the inherent risks of rare disease drug development.

Development of monoclonal antibodies targeting novel pathways in bone biology (e.g., MMP9, FZD receptors), including repurposing of clinical-stage antibodies for new rare disease indications.

The space for rare bone disorders is niche but has growing interest. For FOP, Ipsen's Sohonos (ipalonorcept) is approved, creating a competitive benchmark. For ADO2, there are no approved disease-modifying therapies, positioning vantictumab as a potential first-in-class treatment if successful.